昭衍新药(603127) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was RMB 485,799,506.29, a decrease of 15.51% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was RMB 99,435,565.54, down 58.04% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was RMB 84,926,745.33, a decline of 63.74% compared to the previous year[2] - Year-to-date net profit attributable to shareholders was RMB -70,307,075.11, a decrease of 121.46% compared to the same period last year[2] - Year-to-date revenue was RMB 1,335,156,050.40, down 15.87% year-on-year[2] - Basic earnings per share for Q3 2024 was RMB 0.13, a decrease of 59.38% compared to the same period last year[3] - The net profit for Q3 2024 was -74,244,009.94 RMB, a significant decrease compared to the net profit of 326,197,002.65 RMB in Q3 2023, representing a decline of approximately 122.7%[22] - Operating profit for Q3 2024 was -69,661,013.72 RMB, compared to an operating profit of 392,084,940.00 RMB in the same period last year, indicating a substantial drop[22] - Total operating revenue for the first three quarters of 2024 was CNY 1,335,156,050.40, a decrease of 15.8% compared to CNY 1,587,079,779.38 in the same period of 2023[20] - The total comprehensive income for Q3 2024 was -79,103,195.69 RMB, compared to 336,381,200.67 RMB in Q3 2023, indicating a decline of approximately 123.5%[23] Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,525,184,807.98, a decrease of 5.01% from the end of the previous year[3] - Total assets amounted to CNY 9,525,184,807.98, down from CNY 10,027,159,630.47, a decrease of 5.0%[19] - Total liabilities decreased to CNY 1,534,350,209.75 from CNY 1,746,119,215.39, a reduction of 12.1%[19] - The company's total equity decreased to CNY 7,990,834,598.23 from CNY 8,281,040,415.08, a decline of 3.5%[19] - Inventory decreased to CNY 1,631,793,427.45 from CNY 1,863,081,944.56, a decrease of 12.4%[18] Cash Flow - The net cash flow from operating activities year-to-date was RMB 192,325,709.34, down 57.11% year-on-year[2] - The cash flow from operating activities for the first three quarters of 2024 was 192,325,709.34 RMB, a decrease from 448,440,218.42 RMB in the same period of 2023, showing a decline of approximately 57.1%[24] - The total cash inflow from investment activities for the first three quarters of 2024 was 2,508,098,115.21 RMB, a significant increase from 528,639,464.14 RMB in the same period of 2023[24] - The net cash flow from investing activities was -950,050,766.71, compared to -137,147,755.87 in the previous period, indicating a significant increase in cash outflow for investments[25] - The total cash outflow from financing activities was 248,828,091.97, down from 333,289,197.75 in the previous period, reflecting a reduction in financing costs[25] - The net increase in cash and cash equivalents was -1,013,522,516.10, compared to -8,194,783.60 in the previous period, showing a substantial decline in liquidity[25] - The ending balance of cash and cash equivalents was 1,840,124,511.87, down from 2,891,274,796.93 in the previous period, indicating a decrease in available cash[25] Shareholder Information - The total number of common shareholders at the end of the reporting period was 72,246, with no preferred shareholders having voting rights[9] - The largest shareholder, Feng Yuxia, holds 167,160,633 shares, representing 22.30% of the total shares[10] - The second largest shareholder, HKSCC Nominees Limited, holds 118,974,786 shares, accounting for 15.87%[10] - The company has not reported any changes in the top 10 shareholders due to margin trading or stock lending activities during the reporting period[14] - The top 10 shareholders include several institutional investors, with the largest being a medical index fund[12] Business Operations - The contribution of laboratory service business to net profit year-to-date was RMB -1,705,100, a decline of 100.55% compared to the previous year[4] - The fair value change of biological assets resulted in a net loss of RMB 17,698,420.00 year-to-date[4] - The total new signed orders for the first three quarters amounted to approximately RMB 1.4 billion, with the total outstanding orders at approximately RMB 2.65 billion as of the report date[15] - The outstanding orders execution is influenced by various factors, and investors are advised to pay attention to investment risks[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[11] - The company is focusing on expanding its market presence and enhancing its product development capabilities, although specific new products or technologies were not detailed in the report[20] Research and Development - Research and development expenses for Q3 2024 were 71,085,657.06 RMB, down from 77,639,680.27 RMB in Q3 2023, reflecting a decrease of about 8.1%[22] Accounting and Standards - The company’s financial statements are unaudited as of September 30, 2024[16] - The company has adopted new accounting standards starting in 2024, which may impact future financial reporting[26]